カテゴリ： GlobalData, イギリス, 企業調査

Abzena Plc (ABZA)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Abzena Plc (ABZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8111
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：67
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Abzena Plc (Abzena), formerly Polytherics Group Ltd, is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company’s technologies include antibody discovery and candidate screening, immunology and immunogenicity assessment, manufacture of payload linkers and antibody drug conjugates, development of manufacturing cell lines and process development, and others. Abzena provides its services to biopharmaceutical companies, public and private biotech companies and academic groups, among others. It has its presence in the UK and the US. Abzena is headquartered in Cambridge, the UK.

Abzena Plc (ABZA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11
Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Abzena Plc, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Abzena Raises Funds through Venture Financing 14
Partnerships 16
Abzena Enters into Agreement with Enleofen Bio 16
Abzena Partners with UGA Biopharma 17
Abzena and Baylor Scott & White Research Institute Form Joint Venture 18
Abzena Enters into Agreement with Apitope 19
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 20
PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 21
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 22
Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 23
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 24
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 25
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 26
Antitope Enters Into Research Agreement With NeuroPhage Pharma 27
Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 28
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 29
Licensing Agreements 30
Tmunity Therapeutics Enters into Licensing Agreement with Abzena 30
Telix Pharma Enters into Licensing Agreement with Abzena 31
OBI Pharma Enters into Licensing Agreement with Abzena 32
Abzena Enters into Licensing Agreement for ThioBridge 33
Trieza Therapeutics Enters into Licensing Agreement with Abzena 34
ProtAb Enters into License Agreement with Antitope 35
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 36
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 37
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 38
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 39
Equity Offering 40
Abzena Raises USD31 Million in Private Placement of Shares 40
Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 41
Abzena Raises USD31.8 Million in Private Placement of Shares 42
Abzena Completes IPO 43
Acquisition 44
Astro Bidco to Acquire Abzena 44
Abzena Acquires The Chemistry Research Solution for USD15 Million 46
Abzena Acquires PacificGMP 47
PolyTherics Acquires Antitope For US$20.7 Million 49
Abzena Plc – Key Competitors 50
Abzena Plc – Key Employees 51
Abzena Plc – Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Joint Venture 53
Recent Developments 54
Strategy And Business Planning 54
Jan 05, 2018: Abzena Takes on New Facilities in Cambridge, UK and San Diego 54
Financial Announcements 55
Apr 16, 2018: Abzena: Pre-Close Period Trading Update FY2018 55
Dec 12, 2017: Half year results: Growth strategy progressing 57
Jun 13, 2017: Abzena Announces Full year results: integration and growth seen across the Group, with 41% underlying increase in revenues 58
Feb 21, 2017: Abzena: Trading and business update 59
Corporate Communications 61
Oct 16, 2018: Abzena announces the appointment of Jonathan Goldman, MD as Chief Executive Officer 61
Legal and Regulatory 62
Mar 05, 2018: Abzena: Settlement of claim 62
Government and Public Interest 63
Mar 02, 2017: Abzena, UCL secure £3.5m grant from MRC for autoimmune therapy research 63
Product News 64
Mar 06, 2017: ‘Abzena inside’ product for neurodegenerative conditions moves into Phase II trial 64
Other Significant Developments 65
Mar 26, 2018: Facility Remodelling Completed for Abzena’s New Antibody-Drug Conjugate GMP Manufacturing Suite 65
Nov 14, 2017: Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in ‘Nature’ Article 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67

List of Tables
Abzena Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abzena Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11
Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Abzena Raises Funds through Venture Financing 14
Abzena Enters into Agreement with Enleofen Bio 16
Abzena Partners with UGA Biopharma 17
Abzena and Baylor Scott & White Research Institute Form Joint Venture 18
Abzena Enters into Agreement with Apitope 19
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 20
PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 21
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 22
Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 23
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 24
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 25
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 26
Antitope Enters Into Research Agreement With NeuroPhage Pharma 27
Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 28
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 29
Tmunity Therapeutics Enters into Licensing Agreement with Abzena 30
Telix Pharma Enters into Licensing Agreement with Abzena 31
OBI Pharma Enters into Licensing Agreement with Abzena 32
Abzena Enters into Licensing Agreement for ThioBridge 33
Trieza Therapeutics Enters into Licensing Agreement with Abzena 34
ProtAb Enters into License Agreement with Antitope 35
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 36
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 37
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 38
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 39
Abzena Raises USD31 Million in Private Placement of Shares 40
Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 41
Abzena Raises USD31.8 Million in Private Placement of Shares 42
Abzena Completes IPO 43
Astro Bidco to Acquire Abzena 44
Abzena Acquires The Chemistry Research Solution for USD15 Million 46
Abzena Acquires PacificGMP 47
PolyTherics Acquires Antitope For US$20.7 Million 49
Abzena Plc, Key Competitors 50
Abzena Plc, Key Employees 51
Abzena Plc, Other Locations 52
Abzena Plc, Subsidiaries 52
Abzena Plc, Joint Venture 53

List of Figures
Abzena Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abzena Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Abzena Plc (ABZA)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Applied Genetic Technologies Corp (AGTC)：企業の財務・戦略的SWOT分析
    Summary Applied Genetic Technologies Corp (AGTC) is a pharmaceutical company that provides development of eye disease cures. The company develops treatments for patients that have diseases caused by broken genes. It offers products such as x-linked retinoschisis, achromatopsia, x-linked retinitis pi …
  • BSN medical GmbH：企業の戦略的SWOT分析
    BSN medical GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Icici Bank Ltd
    Icici Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Icici Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Nihon Unisys, Ltd.：企業の戦略・SWOT・財務情報
    Nihon Unisys, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nihon Unisys, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • genOway SA (ALGEN)：企業の財務・戦略的SWOT分析
    genOway SA (ALGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • ANI Pharmaceuticals Inc (ANIP)：製薬・医療：M&Aディール及び事業提携情報
    Summary ANI Pharmaceuticals Inc (ANI) formerly BioSante Pharmaceuticals Inc, is a specialty pharmaceutical company that develops, manufactures and markets pharmaceuticals. The company’s product portfolio encompasses generic and branded tablets indicated for ulcerative colitis; osteoarthritis; rheuma …
  • Novartis AG (NOVN)-製薬・医療分野：企業M&A・提携分析
    Summary Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, n …
  • Nuance Communications, Inc.：企業の戦略・SWOT・財務情報
    Nuance Communications, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nuance Communications, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Kerr Corp：企業の戦略的SWOT分析
    Kerr Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Manila Electric Company：企業の戦略・SWOT・財務情報
    Manila Electric Company - Strategy, SWOT and Corporate Finance Report Summary Manila Electric Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Nagacorp Ltd：企業の戦略・SWOT・財務情報
    Nagacorp Ltd - Strategy, SWOT and Corporate Finance Report Summary Nagacorp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Reece Ltd (REH)：企業の財務・戦略的SWOT分析
    Reece Ltd (REH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Caladrius Biosciences Inc (CLBS)-医療機器分野：企業M&A・提携分析
    Summary Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc is a clinical stage development company that develops and manufactures cell therapy products. The company’s products are based on its proprietary technologies such as Dendritic Cell-Tumor Cell technology; CD34 technology; and T Regu …
  • Marico Limited (MARICO)：企業の財務・戦略的SWOT分析
    Marico Limited (MARICO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Juhl Energy Inc：電力：M&Aディール及び事業提携情報
    Summary Juhl Energy Inc (Juhl Energy), formerly Juhl Wind Inc, specializes in clean and renewable energy. It offers a wide range of clean energy solutions with focus on solar, wind, biomass and natural gas systems. The company helped develop community-based wind farms. It offers comprehensive servic …
  • NGK INSULATORS, LTD.：企業の戦略・SWOT・財務情報
    NGK INSULATORS, LTD. - Strategy, SWOT and Corporate Finance Report Summary NGK INSULATORS, LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Synergy Pharmaceuticals Inc (SGYP)：製薬・医療：M&Aディール及び事業提携情報
    Summary Synergy Pharmaceuticals Inc (Synergy Pharma) is a biopharmaceutical company that develops and commercializes new treatments for gastrointestinal (GI) diseases. The company pioneered its R&D efforts to develop its proprietary uroguanylin-based GI platform. It is also developing analogs of uro …
  • Under Armour Inc (UAA)：企業の財務・戦略的SWOT分析
    Under Armour Inc (UAA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Interconexion Electrica S.A. E.S.P.：発電所・企業SWOT分析
    Interconexion Electrica S.A. E.S.P. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • ProAxsis Ltd：製品パイプライン分析
    Summary ProAxsis Ltd (ProAxsis), formerly ProAx-Sis Ltd, a subsidiary of NetScientific UK Ltd, is a developer of novel, point of care tests for the monitoring of patients with chronic diseases. The company develops proteasetags based point of care tests to offer a visual readout of active proteases …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆